Patients Infected With COVID-19
Conditions
Brief summary
The new outbreak of the SARS-CoV-2 coronavirus is causing an important pandemic affecting a large number of people all-over the world. Vitamin D is a hormone precursor produced by our own body with the help of sunlight which has an important role on adaptive immunity and cellular differentiation, maturation and proliferation of several immune cells. Reduced levels of vitamin D in calves were positioned as the main cause of bovine coronavirus infection in the past. Therefore, it seems plausible that the use of vitamin D as a nutritional ergogenic aid could be a potential intervention to fight against COVID-19 infected patients which remain asymptomatic or which have non-severe and severe symptoms. This study aims to investigate whether the use of vitamin D as an immune modulator agent induces significant improvements of health status and outcomes in non-severe symptomatic patients infected with COVID-19 as well as preventing COVID-19 health deterioration. We hypothesize that vitamin D will significantly improve hard endpoints related to COVID-19 deleterious consequences compared with a usual care control group.
Interventions
DIETARY_SUPPLEMENTVitamin D
The intervention group will receive a single dose of 25000 UI of vitamin D supplement in addition to prescription of NSAIDs, ACE2 inhibitor, ARB or thiazolidinediones, according to clinician criteria, based on the current recommendations. Vitamin D supplementation will be taken in the morning together with a toast with olive oil to facilitate its absorption.
Sponsors
Universidad de Granada
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Non-severe symptomatic patients who present cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia or alternative signs of respiratory infections.
Exclusion criteria
* Patients presenting severe respiratory and/or multisystemic symptoms compatible with advanced COVID-19 and intercurrent acute or severe chronic diseases (i.e. active cancer).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of cumulative death (i.e. mortality) for all causes and for specific causes. | Through study completion, an average of 10 weeks |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Necessity of non-invasive assisted ventilation | Through study completion, an average of 10 weeks | — |
| Intensive care unit admission | Through study completion, an average of 10 weeks | — |
| Post-anesthesia care unit admission | Through study completion, an average of 10 weeks | — |
| Hospital admission | Through study completion, an average of 10 weeks | — |
| Necessity of invasive assisted ventilation | Through study completion, an average of 10 weeks | — |
| Home care and isolation time | Through study completion, an average of 10 weeks | — |
| Bed rest time | Through study completion, an average of 10 weeks | — |
| symptoms' duration (i.e. cough, fever, nasal congestion, gastrointestinal symptoms, fatigue, anosmia, ageusia, diarrhea or alternative signs of COVID-19) | Through study completion, an average of 10 weeks | — |
| Subjective perception of recovery | Through study completion, an average of 10 weeks | It will be measure by questionnaire |
| Medical consultation | Through study completion, an average of 10 weeks | — |
Countries
Spain
Contacts
Primary ContactManuel J Castillo, MD, PhD
Outcome results
None listed